Singapore: Japan-based Nikon has inked a deal with Lonza group to establish a new wholly owned cell and gene therapy contract manufacturing business.

As per the pact, Nikon will have access to Lonza's quality, operating systems, consulting services, facility design and will acquire technical guidance and training in cell therapy.

The collaboration will help Nikon benefit from Lonza's track record in cell manufacturing and advancements in stem cell technology.

Lonza spokeswoman, Ms Collen Floreck said, "Lonza is the recognized world leader in cell therapy manufacturing and under the deal, Lonza will support Nikon by offering training and access to Lonza's operating facilities."

The deal comes as a Japan recently passed a new law that grants conditional approval to regenerative medicines that demonstrate clinical safety and efficacy. Many experts expect Japan to be at the forefront of cell and gene therapy products.